Logo Logo

Publications by Morschhauser, F.

Up a level
Export as [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date
Number of items: 6.

Journal article

Dreyling, M.; Morschhauser, F.; Bouabdallah, K.; Bron, D.; Cunningham, D.; Assouline, S. E.; Verhoef, G.; Linton, K.; Thieblemont, C.; Vitolo, U.; Hiemeyer, F.; Giurescu, M.; Garcia-Vargas, J.; Gorbatchevsky, I.; Liu, L.; Koechert, K.; Pena, C.; Neves, M.; Childs, B. H.; Zinzani, P. L. (2017): Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. In: Annals of Oncology, Vol. 28, No. 9: pp. 2169-2178

Provencio Pulla, M.; Santoro, A.; Mollica, L.; Leppa, S.; Follows, G.; Lenz, G.; Kim, W. S.; Nagler, A.; Panayiotidis, P.; Demeter, J.; Ozcan, M.; Kosinova, M.; Bouabdallah, K.; Morschhauser, F.; Ishida, T.; Huang, L.; Garcia-Vargas, J.; Childs, B. H.; Zinzani, P. L.; Dreyling, M. (2017): Copanlisib treatment in patients with relapsed or refractory indolent B-cell lymphoma: Subgroup analyses from the CHRONOS-1 study. In: Annals of Oncology, Vol. 28

Dreyling, M.; Santoro, A.; Mollica, L.; Leppa, S.; Follows, G. A.; Lenz, G.; Kim, W. S.; Nagler, A.; Panayiotidis, P.; Demeter, J.; Ozcan, M.; Kosinova, M.; Bouabdallah, K.; Morschhauser, F.; Stevens, D. A.; Trevarthen, D.; Giurescu, M.; Kupit, L.; Childs, B. H.; Zinzani, P. L. (2017): Copanlisib (COP) in patients with relapsed or refractory indolent B-cell lymphoma: primary results of the pivotal Chronos-1 study. In: Oncology Research and Treatment, Vol. 40: p. 12

Younes, A.; Hilden, P.; Coiffier, B.; Hagenbeek, A.; Salles, G.; Wilson, W.; Seymour, J. F.; Kelly, K.; Gribben, J.; Pfreunschuh, M.; Morschhauser, F.; Schoder, H.; Zelenetz, A. D.; Rademaker, J.; Advani, R.; Valente, N.; Fortpied, C.; Witzig, T. E.; Sehn, L. H.; Engert, A.; Fisher, R. I.; Zinzani, P.-L.; Federico, M.; Hutchings, M.; Bollard, C.; Trneny, M.; Elsayed, Y. A.; Tobinai, K.; Abramson, J. S.; Fowler, N.; Goy, A.; Smith, M.; Ansell, S.; Kuruvilla, J.; Dreyling, M.; Thieblemont, C.; Little, R. F.; Aurer, I.; Oers, M. H. J. van; Takeshita, K.; Gopal, A.; Rule, S.; Vos, S. de; Kloos, I.; Kaminski, M. S.; Meignan, M.; Schwartz, L. H.; Leonard, J. P.; Schuster, S. J.; Seshan, V. E. (2017): International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). In: Annals of Oncology, Vol. 28, No. 7: pp. 1436-1447

Dreyling, M. H.; Morschhauser, F.; Bouabdallah, K.; Cunningham, D.; Bron, D.; Linton, K.; Assouline, S.; Verhoef, G.; Thieblemont, C.; Vitolo, U.; Garcia-Vargas, J.; Gorbatchevsky, I; Neves, M.; Grunert, J.; Hiemeyer, F.; Childs, B. H.; Zinzani, P. L. (2016): Phase 2a study of the phosphatidylinositol-3-kinase (PI3K) inhibitor copanlisib in patients with relapsed/refractory, indolent or aggressive lymphoma. In: Oncology Research and Treatment, Vol. 39: p. 310

Dreyling, M.; Morschhauser, F.; Bouabdallah, K.; Cunningham, D.; Bron, D.; Linton, K.; Assouline, S.; Verhoef, G.; Thieblemont, C.; Vitolo, U.; Garcia-Vargas, J.; Gorbatchevsky, I.; Neves, M.; Grunert, J.; Hiemeyer, F.; Childs, B. H.; Zinzani, P. L. (2016): Phase 2a study of the Phosphatidylinositol-3-Kinase (PI3K) inhibitor Copanlisib in patients with relapsed/refractory, indolent or aggressive lymphoma. In: Haematologica, Vol. 101: p. 104

This list was generated on Fri Aug 7 00:49:28 2020 CEST.